Literature DB >> 7543276

Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia.

M Hornberg1, V Arolt, I Wilke, A Kruse, H Kirchner.   

Abstract

Recently, several lines of evidence have suggested the possible of immunological dysfunction in the pathogenesis of schizophrenia. We therefore investigated the ability to produce interferons and lymphokines in response to mitogenic or viral stimulation in a whole blood assay of 37 schizophrenic patients (DSM-III-R) and of 42 healthy blood donors. Phytohaemagglutinin (PHA) was used for the induction of interleukin-2 (IL-2), interferon gamma (INF gamma), interleukin-6 (IL-6) and the soluble interleukin-2 receptor (sIL-2R) and Newcastle Disease Virus (NDV) for the induction of interferon alpha 2 (INF alpha 2). All lymphokines and, in addition, the sIL-2R in the sera were determined by ELISA technique. The psychopathological status of the patients was assessed by psychiatrists according to internationally accepted standards. The patient group showed a trend to lower levels of the interferons alpha 2 and gamma and a significant decrease of IL-2 production. The sIL-2R levels were significantly increased in the sera of schizophrenic patients. The latter increase was associated with a poor assessment of prognosis (Strauss and Carpenter). This association appears to be of interest. However, its significance is not understood, since longitudinal studies could not be performed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543276     DOI: 10.1016/0920-9964(94)00046-b

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

Review 1.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

3.  Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables.

Authors:  Ellen E Lee; Suzi Hong; Averria Sirkin Martin; Lisa T Eyler; Dilip V Jeste
Journal:  Am J Geriatr Psychiatry       Date:  2016-10-17       Impact factor: 4.105

Review 4.  Methodological Issues in Cytokine Measurement in Schizophrenia.

Authors:  Maju Mathew Koola
Journal:  Indian J Psychol Med       Date:  2016 Jan-Feb

5.  Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.

Authors:  N Müller; M Empl; M Riedel; M Schwarz; M Ackenheil
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

6.  Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.

Authors:  I Wilke; V Arolt; M Rothermundt; C Weitzsch; M Hornberg; H Kirchner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

7.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

8.  Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population.

Authors:  Yuichiro Watanabe; Ayako Nunokawa; Masako Shibuya; Naoshi Kaneko; Hiroyuki Nawa; Toshiyuki Someya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-20       Impact factor: 5.270

9.  Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia.

Authors:  Mark H Rapaport; Catherine Bresee
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 10.  [Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness].

Authors:  A Schuld; D Hinze-Selch; Th Pollmächer
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.